Isatuximab Shows Promise in Enhancing PFS for Patients with Multiple Myeloma

Source: Pharmacy Times articles

Isatuximab (Sarclisa; Sanofi) in combination with standard-of-care significantly improved progression-free survival in patients with newly diagnosed multiple myeloma.
Read More